Abstract
The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) was a 25,620 patient study program comparing telmisartan with ramipril or the combination thereof in patients at increased cardiovascular risk. Ramipril had previously been proven to prevent cardiovascular events in a similar population within the HOPE-trial. However, ramipril and other ACE inhibitors (ACE-Is) may have limited tolerability that might restrict their use in patients requiring secondary prevention, whereas angiotensin receptor blockers (ARBs) are suggested to be better tolerated. However, no ARB had been compared with the standard treatment, ramipril, in these cardiovascular patients at increased risk. ONTARGET showed that telmisartan was as effective as ramipril in preventing cardiovascular events, but was better tolerated. The combination of ramipril and telmisartan was not superior to either monotherapy. Taken together, ONTARGET demonstrated that telmisartan is as effective as ramipril in a broad cardiovascular increased-risk population in the middle of the cardiovascular continuum. In these patients who are intolerant to ACE-Is or who do not achieve blood pressure control, the ARB with the best evidence for secondar...Continue Reading
References
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Jan 5, 2002·The New England Journal of Medicine·J N CohnUNKNOWN Valsartan Heart Failure Trial Investigators
Apr 9, 2002·Lancet·Björn DahlöfUNKNOWN LIFE Study Group
Sep 19, 2003·Lancet·John J V McMurrayUNKNOWN CHARM Investigators and Committees
Sep 19, 2003·Lancet·K M Fox, UNKNOWN EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
Jun 23, 2004·Lancet·Stevo JuliusUNKNOWN VALUE trial group
Jun 25, 2004·American Heart Journal·Koon TeoUNKNOWN ONTARGET/TRANSCEND Investigators
Nov 9, 2004·Lancet·Bo CarlbergLars Hjalmar Lindholm
Nov 9, 2004·The New England Journal of Medicine·Eugene BraunwaldUNKNOWN PEACE Trial Investigators
Apr 2, 2008·The New England Journal of Medicine·UNKNOWN ONTARGET InvestigatorsCraig Anderson
Sep 2, 2008·Lancet·S YusufP Sleight
Feb 10, 2009·Lancet·Andreas LinkSimina Selejan
Feb 20, 2009·Journal of Human Hypertension·B WilliamsJ M Neutel
Jun 10, 2009·Journal of Hypertension·Peter SleightUNKNOWN ONTARGET investigators